logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings | Collections | MSF Science Portal
Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings

Mini-Lab—MSF's simplified bacteriology laboratory for low-resource settings

Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. One key limitation in most of these settings is a lack of clinical bacteriology laboratory capacity, which leaves medical providers without ways to accurately diagnose patient infections and to tailor antibiotic treatment accordingly.

To help fill this critical gap, MSF and partners have developed the Mini-Lab—a small-scale, standalone lab that is easy to transport, set up and operate by staff after only a short training. Its six modules are stocked with everything needed to diagnose common bloodstream and urinary tract infections and to perform antibiotic sensitivity testing using methods adapted to extremely hot climates and remote settings.

With Mini-Lab now being rolled out to selected MSF projects, here we highlight the background to its development and some of the research behind the bacteriological tests it incorporates.

Collection Content

Journal Article
|
Research

Validation of three MicroScan® antimicrobial susceptibility testing plates designed for low-resource settings

Ronat JB, Oueslati S, Natale A, Kesteman T, Elamin W,  et al.
2022-08-30 • Diagnostics
2022-08-30 • Diagnostics
Easy and robust antimicrobial susceptibility testing (AST) methods are essential in clinical bacteriology laboratories (CBL) in low-resource settings (LRS). We evaluated the Beckman Coul...
Journal Article
|
Research

Biphasic versus monophasic manual blood culture bottles for low-resource settings: an in-vitro study

Ombelet S, Natale A, Ronat JB, Kesteman T, Vandenberg O,  et al.
2021-12-13 • Lancet Microbe
2021-12-13 • Lancet Microbe
BACKGROUND
Manual blood culture bottles (BCBs) are frequently used in low-resource settings. There are few BCB performance evaluations, especially evaluations comparing them with aut...
Journal Article
|
Review

AMR in low-resource settings: Médecins Sans Frontières bridges surveillance gaps by developing a turnkey solution, the Mini-Lab

Ronat JB, Natale A, Kesteman T, Andremont A, Elamin W,  et al.
2021-10-01 • Clinical Microbiology and Infection
2021-10-01 • Clinical Microbiology and Infection
BACKGROUND
In low- and middle-income countries (LMICs), data related to antimicrobial resistance (AMR) are often inconsistently collected. Humanitarian, private and non-governmental ...
Conference Material
|
Video

Development of an all-in-one transportable clinical bacteriology laboratory: Feedback from testing the MSF Mini-Lab development project in Haiti

Ronat JB
2021-08-25 • MSF Scientific Days Asia 2021
2021-08-25 • MSF Scientific Days Asia 2021
Journal Article
|
Research

Evaluation of MicroScan bacterial identification panels for low-resource settings

Ombelet S, Natale A, Ronat JB, Vandenberg O, Hardy L,  et al.
2021-02-19 • Diagnostics
2021-02-19 • Diagnostics
Bacterial identification is challenging in low-resource settings (LRS). We evaluated the MicroScan identification panels (Beckman Coulter, Brea, CA, USA) as part of Médecins Sans Frontiè...
Journal Article
|
Commentary

The Mini-Lab: accessible clinical bacteriology for low-resource settings

Natale A, Ronat JB, Mazoyer A, Rochard A, Boillot B,  et al.
2020-06-01 • Lancet Microbe
2020-06-01 • Lancet Microbe
Journal Article
|
Commentary

Antibiotic resistance in conflict settings: lessons learned in the Middle East

Kanapathipillai R, Malou N, Hopman J, Bowman C, Yousef N,  et al.
2019-04-10 • Journal of Antimicrobial Chemotherapy
2019-04-10 • Journal of Antimicrobial Chemotherapy
Médecins Sans Frontières (MSF) has designed context-adapted antibiotic resistance (ABR) responses in countries across the Middle East. There, some health systems have been severely damag...
Journal Article
|
Commentary

Clinical bacteriology in low-resource settings: today's solutions

Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J,  et al.
2018-03-05 • Lancet Infectious Diseases
2018-03-05 • Lancet Infectious Diseases
Low-resource settings are disproportionately burdened by infectious diseases and antimicrobial resistance. Good quality clinical bacteriology through a well functioning reference laborat...

See more collections

World NTD Day
World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

Healthcare needs of older people in humanitarian settings
Healthcare needs of older people in humanitarian settings

Globally, the number of older people is rapidly increasing, with those aged 60+ expected to more than double by 2050—yet in humanitarian crises, they remain one of the most neglected groups. Older adults often face higher risks due to chronic illnesses, mobility issues, and limited access to appropriate care, especially in low-resource or emergency settings. Despite these needs, humanitarian responses rarely prioritize them, and data on their health and mortality are often lacking.


This collection reflects MSF’s ongoing examination of its own data and practices to identify pathways toward more age-inclusive services in humanitarian crises. It includes analysis of data from MSF-supported mental health services, inpatient departments, and sexual violence services, and further offers several calls to action and reflections on why older people remain overlooked in humanitarian crises. However, MSF also acknowledges major challenges remain, including inadequate age-inclusive services, data gaps, and the need for more geriatric expertise.


Watch this space for more publications from a Lancet Healthy Longevity series on healthcare rights and needs of older people.


Snake envenoming: a neglected crisis
Snake envenoming: a neglected crisis

Every year 2 million or more people fall victim to snakebite envenoming, mostly in poor, rural communities of Africa, Asia and Latin America. Between 83,000—138,000 of them die, while hundreds of thousands more suffer debilitating long-term complications or disabilities.


Although some antivenom medicines are highly effective when used promptly and appropriately, many snakebite victims get no treatment at all. Those who do may receive antivenoms which don’t work against the type of snake that bit them, or were not rigorously tested for safety and effectiveness.


To mark World Snakebite Awareness Day on September 19th, the Collection linked below brings together recent MSF work on this highly neglected disease. Several articles and conference presentations help fill evidence gaps on the burden of disease and its impacts or on treatment outcomes with specific antivenoms in specific regions. Others examine how to tackle the formidable challenges of availability and affordability, the absence of regulatory oversight for making, testing and registering antivenoms, and the anemic R&D pipeline for new products—all of which impede access for patients to safe, effective treatment tailored to local snake species.

View All Collections